Compare AFLAC Incorporated (AFL) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AFLAC Incorporated vs Tilray Brands Inc — how do they compare? AFLAC Incorporated trades at $121.41 (market cap $61.84B), while Tilray Brands Inc trades at $4.37 (market cap $532.10M). The key difference: AFLAC Incorporated is far larger — about 116.2× Tilray Brands Inc's market cap, and AFLAC Incorporated pays a 2.01% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| AFL | TLRY | |
|---|---|---|
Market Cap | $61.84B | $532.10M |
Sector | Financials | Health |
52-Week High | $121.49 | $21.00 |
52-Week Low | $98.09 | $4.31 |
Enterprise Value | $70.50B | $629.24M |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aflac (AFL) trades at $121.49, up 0.5% with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a 25.32% net income margin and 16.47% ROE, though recent Q1 2026 earnings missed expectations. Analyst consensus is mixed with 28% buy ratings and a $113.57 price target below current levels. Recent developments include strong dividend performance and upcoming Q2 2026 results announcement on August 6, 2026.
The outlook remains cautiously optimistic with solid profitability and dividend stability, but faces headwinds from recent earnings misses and premium valuation pressure. Key opportunities include continued growth in Japan and U.S. markets, while risks involve medical cost inflation and uneven revenue trends. The stock's current premium to analyst targets suggests limited near-term upside potential.
TLRY trades at $4.38, down 5.19% today, reflecting ongoing investor concerns about profitability despite revenue growth to $821 million in 2025. The stock shows bearish technical signals with key support at $4 and resistance at $5. Recent acquisitions and medical cannabis expansion provide growth avenues, but negative net income margins and cash flow challenges persist. Analyst consensus remains cautious with 65% hold ratings.
TLRY presents a high-risk opportunity with potential upside from strategic acquisitions and market expansion, but significant challenges include persistent losses, negative cash flow, and regulatory uncertainties. The stock's low P/S (0.54) and P/B (0.35) ratios suggest undervaluation, but profitability remains the critical hurdle for sustainable growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
